Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 16;83(17):2824–2838. doi: 10.1158/0008-5472.CAN-22-3682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. CD36 inhibition delays AML relapse after chemotherapy. A, Percentage of mice engrafted with U937 cells transduced with shCtrl (n = 11) or shCD36 (n = 11) and treated with vehicle or AraC, surviving over time after treatment. B, Same as A, with OCIAML3 [shCtrl (n = 18) and shCD36 (n = 22)]. C, Percentage of mice engrafted with U937 cells surviving over time after treatment with the indicated combinations of PBS or AraC administered for the first 5 days, with either control IgG or FA6-152 anti-CD36 antibody injected three times/week (n = 7 PBS-IGG; n = 7 PBS-anti-CD36; n = 7 AraC-IGG; n = 6 AraC-anti-CD36). D, Venn diagram of significantly cooverexpressed genes along with CD36 in TCGA, Verhaak, and BeatAML cohorts. E, Gene set enrichment analysis of CD36 gene signature in AraC versus untreated AML blasts from three different transcriptomic analyses. A–C, log-rank (Mantel–Cox) test. E, One sample t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. — CD36 inhibition delays AML relapse after chemotherapy. A, Percentage of mice engrafted with U937 cells transduced with shCtrl (n = 11) or shCD36 (n = 11) and treated with vehicle or AraC, surviving over time after treatment. B, Same as A, with OCIAML3 [shCtrl (n = 18) and shCD36 (n = 22)]. C, Percentage of mice engrafted with U937 cells surviving over time after treatment with the indicated combinations of PBS or AraC administered for the first 5 days, with either control IgG or FA6-152 anti-CD36 antibody injected three times/week (n = 7 PBS-IGG; n = 7 PBS-anti-CD36; n = 7 AraC-IGG; n = 6 AraC-anti-CD36). D, Venn diagram of significantly cooverexpressed genes along with CD36 in TCGA, Verhaak, and BeatAML cohorts. E, Gene set enrichment analysis of CD36 gene signature in AraC versus untreated AML blasts from three different transcriptomic analyses. A–C, log-rank (Mantel–Cox) test. E, One sample t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.